Sol-Gel Technologies (SLGL) Total Current Liabilities (2016 - 2026)
Sol-Gel Technologies (SLGL) reported Total Current Liabilities of $6.3 million for Q1 2026, up 38.05% year-over-year from $4.6 million in Q1 2025, and up 2.3% quarter-over-quarter from $6.2 million in Q4 2025.
Sol-Gel Technologies (SLGL) Total Current Liabilities (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Total Current Liabilities data on file, last reported at $6.3 million in Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $6.3 million, up 38.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.3 million (up 38.05% YoY), and the FY2025 annual result was $6.2 million, up 16.76% from the prior year.
- Total Current Liabilities rose to $6.3 million in Q1 2026 per SLGL's latest filing, from $6.2 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $6.5 million in Q3 2024 and troughed at $2.6 million in Q3 2022.
- A 5-year average of $4.8 million and a median of $5.0 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities sank 72.74% in 2022, then soared 75.72% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $3.3 million in 2022, then jumped by 35.84% to $4.5 million in 2023, then rose by 16.87% to $5.3 million in 2024, then climbed by 16.76% to $6.2 million in 2025, then rose by 2.3% to $6.3 million in 2026.
- Business Quant data shows SLGL's Total Current Liabilities at $6.3 million in Q1 2026, $6.2 million in Q4 2025, and $6.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 6.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.31 Mn |
| Dec 31, 2025 | 6.17 Mn |
| Sep 30, 2025 | 6.15 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Mar 31, 2025 | 4.57 Mn |
| Dec 31, 2024 | 5.29 Mn |
| Sep 30, 2024 | 6.53 Mn |
| Jun 30, 2024 | 5.20 Mn |
| Mar 31, 2024 | 5.23 Mn |
| Dec 31, 2023 | 4.52 Mn |
| Sep 30, 2023 | 4.51 Mn |
| Jun 30, 2023 | 5.67 Mn |
| Mar 31, 2023 | 3.92 Mn |
| Dec 31, 2022 | 3.33 Mn |
| Sep 30, 2022 | 2.60 Mn |
| Jun 30, 2022 | 3.23 Mn |
| Mar 31, 2022 | 4.21 Mn |
| Dec 31, 2021 | 11.69 Mn |
| Sep 30, 2021 | 9.53 Mn |
| Jun 30, 2021 | 5.16 Mn |